TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
+$0.14 today
- Market cap
- $87.31M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
Volume 0.19M
Average 0.85M
HURA Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
TuHURA Biosciences, Inc.NASDAQ: HURA
Net Receivables · Q1 FY2026 · quarter ended Mar 2026
Net receivables remains negative
Q1 FY2026 net receivables was $0, compared with $95.55K a year earlier.
Context
- Net receivables amounted to 0.0% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Net receivables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps falling in the next quarterly balance sheet after a -100.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 222.7K | -33.4% |
| FY2023 | 2023-12-31 | 334.44K | +229.7% |
| FY2022 | 2022-12-31 | 101.42K | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How HURA compares with its peers on the latest reported figures
- HURA's Mar 2026 net receivables of $0 is the 8th highest of the 9 companies compared; the peer median is $1.74M.
- Its year-over-year change of -100.0% is the 8th highest of 9, against a peer median of -33.2%.
- Net receivables amounts to 0.0% of total assets for HURA, versus a peer median of 1.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $54.06M | +15171.8% | -12.6% | 29.0% | |
| Mar 2026 | $4.26M | -20.5% | -5.3% | 1.6% | |
| Mar 2026 | $3.66M | -23.5% | +39.3% | 10.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $2.72M | -42.9% | -13.3% | 4.1% |
| Mar 2026 | $772K | +105.3% | — | 0.6% | |
| Mar 2026 | $233K | -94.7% | — | 0.2% | |
| Mar 2026 | $44K | -99.8% | +186.1% | 0.1% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | -96.6% | 0.0% | |
| Peer median (excluding HURA) | $1.74M | -33.2% | -9.0% | 1.1% | |
Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 5.55M | 14.25M | 3.67M | 12.66M | 3.62M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 101.42K | 334.44K | 222.7K | 0 |
| Inventory | 0 | 0 | 0 | 214.7K | 0 |
| Other Current Assets | 135.13K | 390.35K | 159.33K | 316.35K | 1M |
| Total Current Assets | 5.68M | 14.74M | 4.16M | 19.61M | 4.62M |
| Property, Plant & Equipment (Net) | 617.14K | 418.55K | 202.99K | 322.53K | 685.17K |
| Goodwill | 0 | 0 | 0 | 0 | 10.74M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 103.9K | 33.77K | 0 | 33.77K | 11.31M |
| Total Non-current Assets | 721.04K | 452.32K | 202.99K | 356.3K | 22.73M |
| Total Assets | 6.4M | 15.2M | 4.36M | 19.97M | 27.35M |
| Account Payables | 413.79K | 1.92M | 1.87M | 3.15M | 3.77M |
| Short-term Debt | 644.07K | 0 | 0 | 0 | 197.35K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 456K | 675K | 137K | 1.16M | 1.53M |
| Total Current Liabilities | 7.15M | 2.87M | 3.6M | 5.33M | 5.92M |
| Long-term Debt | 0 | 0 | 2.32M | 0 | 303.63K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 197.92K |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 0 | 20.74K | 2.32M | 42.7K | 501.55K |
| Total Liabilities | 7.15M | 2.89M | 5.92M | 5.37M | 6.42M |
| Common Stock | 4.53K | 4.53K | 6.8K | 42.32K | 59.34K |
| Retained Earnings | (49.48M) | (59.16M) | (88.47M) | (111.12M) | (141.18M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (747.82K) | 12.3M | (1.56M) | 14.59M | 20.93M |
| Total Debt | 644.07K | 138.22K | 2.34M | 202.54K | 700.02K |
| Net Debt | (4.9M) | (14.11M) | (1.32M) | (12.45M) | (2.92M) |
TuHURA Biosciences, Inc.
NASDAQ:HURA
Intrinsic Alpha fair value
Locked
Current Price
$1.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.